^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PH001

i
Other names: PH001, YK-029A, YK-209A
Company:
Suzhou Puhe Pharma
Drug class:
EGFR inhibitor
Related drugs:
1year
Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naïve patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations: A phase I trial. (PubMed, J Thorac Oncol)
YK-029A showed manageable safety and was tolerable in patients with NSCLC harboring EGFR mutations and showed promising antitumor activity in untreated patients with EGFR ex20ins mutations.
P1 data • PK/PD data • Journal • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
PH001
over1year
Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC. (PubMed, Eur J Med Chem)
Furthermore, YK-029A exhibited significant antitumor activity in EGFRex20ins-driven patients-derived xenograft (PDX) models, preventing tumor progression or causing tumor regression at well-tolerated dosages. Based on the outcomes of preclinical efficacy and safety studies, YK-029A will enter phase Ⅲ clinical trials for the treatment of EGFRex20ins NSCLC.
Journal
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 20 insertion • EGFR exon 20 mutation
|
PH001
over1year
New P3 trial • EGFR exon 20
|
HER-2 (Human epidermal growth factor receptor 2)
|
EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
|
cisplatin • carboplatin • pemetrexed • PH001
over1year
New P1/2 trial • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
|
PH001